Keywords
antifungal
azoles
fluconazole
CLAE-UV
How to Cite
Abstract
The polyenes and azoles antifungals comprise the imidazoles that are represented by miconazole nitrate and ketoconazole, and the triazolics are represented by fuconazole and itraconazole. They are widely prescribed for the treatment of systemic infections caused by fungi, especially in immunocompromised patients. The compounded pharmaceuticals are developed to attend individualized treatment and in Brazil they are regulated by the RDC No. 67 which established the Good Practices for Manipulated of Magistrates and Officinal Preparations for human use in Pharmacy (GPMP). The institute received samples of manipulated capsules identified as fluconazole to verify the identity of the product. The method employed was ketoconazole essay from USP-28 which have the following modifications: column, length wavelength, flow, temperature at 25ºC;the mobile phase was adjusted to pH 5.6 with glacial acetic acid. used: Shimadzu HPLC CLASS-VP10, standards of miconazole nitrate and the bases of fluconazole, itraconazole, ketoconazole, secnidazole, tioconazole and metronidazole. These standards were prepared at concentration 100µg/mL, as well as the solutions of the individual contents of the capsules. After the chromatographic development of the samples and the standards, retention times were not similar between the capsules and standards. Conclusion was that the content of the capsules was not fluconazole. The chromatographic system proved effective in identification of six antifungals that have similar chemical structures and they showed different times of elution just like the antiparasitic metronidazole which has different chemical structure. This method could be a choice for the analysis of antifungal if there were complaints about the identity of the drug.
References
Bennet JE. Antimicrobial agents. In: Goodman and Gilman’s: the pharmacological basis of therapeutics. 9 ed. New York: Pergamon Press; 1996, p.1175-8.
Martindale. The complete drug reference. 34 ed. London: The Royal Pharmaceutical Society of Great Britain. 2005, p. 398-9.
Caillot D, Bassaris HA, McGeer AC, Arthur C, Prentice WS, De Beule K. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignances, chronicgranulomatous disease, or AIDS. Clin Infect Dis. 2001;33:83-90.
Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal prophylaxis with plasma level. Mycoses. 1989;32(1):103.
Girois SB, Chapuis F, Decullier E, Revol BG. Adverse effects of antifungical therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2005;24:119-30.
Brasil. Resolução RDC n° 67, de 8 de outubro de 2007. Dispõe sobre Boas Práticas de Manipulação de Preparações Magistrais e Oficinais para Uso Humano em Farmácias. Diário Oficial da União. Poder Executivo. 9 out 2007.
United States Pharmacopoeia. 28 ed. Rockville: United States Pharmacopeia l Convention; 2005. p. 1099. 8. Boucher AB, King RS, Wandschneider WI, Hanes DS, Herring IV, Canad WT, Hess MM. Fluconazole pharmacokinetics in burn patients. Antimicrob Agents Chemother. 1998;42(4):930-3.
Zanini AC, Oga S. Farmacologia aplicada. 5 ed. São Paulo: Atheneu; 1994. p. 533.
Martindale. The complete drug reference. 34.ed. London: The Royal Pharmaceutical Society of Great Britain. 2005, p. 607.
Markman BEO, Koschtschak MRW, Auricchio MT. Otimização e validação de método farmacopéico para avaliar possíveis desvios de qualidades de matérias-primas e cápsulas manipuladas contendo hormônios tiroidianos. Rev Inst Adolfo Lutz. 2007;66(3):268-74
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2009 Blanca Elena Ortega Markman, Maria Regina Walter Koschtschak, Olívia Uessugui, Roberta Fiusa Magnelli Fiusa Magnelli, Elizabeth Meihuey Wu